CANSINO BIOLOGICS IN

6185
End-of-day quote. End-of-day quote  - 09/24
280.2HKD -0.64%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 62 62938 163
Entreprise Value (EV)2 58 32433 090
P/E ratio -86,4x11,6x
Yield -0,00%
Capitalization / Revenue 3 377x3,82x
EV / Revenue 3 145x3,31x
EV / EBITDA -158x7,38x
Price to Book 6,06x5,07x
Nbr of stocks (in thousands) 247 450114 779
Reference price (CNY) 149233
Announcement Date 02/25/2021-
Previous period Next period
1 HKD in Million
2 CNY in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 18,59 984
EBITDA1 -3694 483
Operating profit (EBIT)1 -4014 439
Operating Margin -2 162%44,5%
Pre-Tax Profit (EBT)1 -3975 421
Net income1 -3975 282
Net margin -2 139%52,9%
EPS2 -1,7220,1
Dividend per Share2 -0,00
Announcement Date 02/25/2021-
Previous period Next period
1 CNY in Million
2 CNY
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 4 3045 073
Leverage (Debt / EBITDA) 11,7x-1,13x
Free Cash Flow1 -739727
ROE (Net Profit / Equities) -10,5%58,1%
Shareholders' equity1 3 7719 095
ROA (Net Profit / Asset) -9,30%59,3%
Assets1 4 2668 913
Book Value Per Share2 24,545,9
Cash Flow per Share2 -2,035,31
Capex1 270375
Capex / Sales 1 455%3,76%
Announcement Date 02/25/2021-
Previous period Next period
1 CNY in Million
2 CNY
Financial Ratios
Size 2021e 2022e
Capitalization 38 163 M CNY -
Entreprise Value (EV) 33 090 M CNY 20 523 M CNY
Valuation 2021e 2022e
P/E ratio (Price / EPS) 11,6x 5,69x
Capitalization / Revenue 3,82x 1,64x
EV / Revenue 3,31x 1,42x
EV / EBITDA 7,38x 3,36x
Yield (DPS / Price) 0,00% 0,00%
Price to book (Price / BVPS) 5,07x 2,70x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 44,5% 47,7%
Operating Leverage (Delta EBIT / Delta Sales) 0,02x 1,13x
Net Margin (Net Profit / Revenue) 52,9% 42,0%
ROA (Net Profit / Asset) 59,3% 58,0%
ROE (Net Profit / Equities) 58,1% 57,3%
Rate of Dividend 0,01% 0,00%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   3,76% 1,62%
Cash Flow / Sales 6,11% 18,2%
Capital Intensity (Assets / Sales) 0,89x 0,72x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
Change in Enterprise Value/EBITDA
EPS & Dividend